FDA plans to reclassify certain peptides Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 16 April, 2026

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

presented by CNS-3D Brain Organoids Pre­dict Clin­i­cal Seizure Li­a­bil­i­ty, New Study Da­ta

SPOTLIGHT Biotech stocks are on a tear again: Signal Insights

news Lilly's obesity pill heads for diabetes filing after heart risk trial Updated: FDA will reclassify at least a dozen peptides, teeing up potential telehealth win Women’s health biotech Freya Biosciences advances microbial therapy for IVF implantation failure In vivo autoimmune CAR-T race grows as two RNA startups enter the clinic

Apr 28 12:30 pm ET Connection ≠ continuity: Rethinking long-term evidence in the age of tokenization sponsored by PicnicHealth Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher

The R&D 15 is John Carroll’s annual reckoning with where biopharma’s biggest players are really investing — and where they’re not. This year he’s back at the table with some of the industry’s top research chiefs for a frank, one-hour conversation on the trends shaping drug development in 2026 and beyond. Join us.

in case you missed it 1. Former FDA cancer chief Pazdur warns of the political 'breach' of review teams 2. Bioregnum The Q1 deal report: China dominates big licensing deals as M&A starts 2026 with a bang 3. Revolution Medicines prices $2B raise as XBI reaches heights not seen since pandemic 4. Beeline Medicines emerges as Bristol Myers' partner for shelved immunology drugs 5. News Briefing Biogen filing reveals Apellis deal details; Telix raises $600M; Obsidian to go public 6. Terremoto raises $108M to make an 'earthquake' in small molecule space 7. Suntory to buy Daiichi Sankyo’s health unit for $1.6B